Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: The role of palivizumab

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 9, 2010, Pages 1265-1271

  Kassis, Christelle ^a   Champlin, Richard E ^a   Hachem, Ray Y ^a   Hosing, Chitra ^a   Tarrand, Jeffrey J ^a   Perego, Cheryl A ^a   Neumann, Joyce L ^a   Raad, Issam I ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hematopoietic stem cell transplantation; Outbreak; Respiratory Syncytial Virus

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; EDUCATION; EPIDEMIC; FEMALE; HAND WASHING; HEALTH CARE PERSONNEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITAL PERSONNEL; HUMAN; IMMUNOPROPHYLAXIS; INFECTION CONTROL; MALE; PATIENT; PATIENT CARE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SCREENING; SINGLE DRUG DOSE; SYMPTOM; VIRUS DETECTION; VIRUS PNEUMONIA; VIRUS TRANSMISSION;

EID: 77955511924     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.011     Document Type: Article

References (54)

1. Izurieta H.S., Thompson W.W., Kramarz P., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342:232-239.
2. Falsey A.R., Treanor J.J., Betts R.F., et al. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992, 40:115-119.
3. Shay D.K., Holman R.C., Newman R.D., et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999, 282:1440-1446.
4. Fenton C., Scott L.J., Plosker G.L. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs 2004, 6:177-197.
5. Sable C.A., Hayden F.G. Orthomyxoviral and paramyxoviral infections in transplant patients. Infect Dis Clin N Am 1995, 9:987-1003.
6. Whimbey E., Champlin R., Englund J., et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995, 16:393.
7. Falsey A.R., Hennessey P.A., Formica M.A., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
8. Osterweil D., Norman D. An outbreak of an influenza-like illness in a nursing home. J Am Geriatr Soc 1990, 38:659-662.
9. Falsey A.R. Noninfluenza respiratory virus infection in long-term care facilities. Infect Control Hosp Epidemiol 1991, 12:602-608.
10. Abdallah A., Rowland K.E., Schepetiuk S.K., To L.B., Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003, 32:195-203.
11. Harrington R.D., Hooton T.M., Hackman R.C., et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992, 165:987-993.
12. Jalal H., Bibby D.F., Bennett J., et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol 2007, 1690-1696.
13. Isaacs D., Dickson H., O'Callaghan C., Sheaves R., Winter A., Moxon E.R. Handwashing and cohorting in prevention of hospital acquired infections with respiratory syncytial virus. Arch Dis Child 1991, 66:227-231.
14. Madge P., Paton J.Y., McColl J.H., Mackie P.L. Prospective controlled study of four infection control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992, 340:1079-1083.
15. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IG IV. Pediatrics 1998, 102:1211-1216. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Foetus and Newborn.
16. Carbonell X., Giuffre L., Kimpen J., et al. Guidelines for the use of Synagis palivizumab-a humanized monoclonal antibody, for the prevention of RSV disease in high-risk infants: a consensus opinion. Infect Med 1999, 16:1-5.
17. Meissner H.C., Welliver R.C., Chartrand S.A., et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999, 18:223-231.
18. Landry M.L., Ferguson D. SimuFluor respiratory screen for rapid detection of multiple respiratory viruses in clinical specimens by immunofluorescence staining. J Clin Microbiol 2000, 38:708-711.
19. Couch R.B., Englund J.A., Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997, 102:2-9.
20. Chemaly R.F., Ghosh S., Bodey G.P., et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006, 85:278-287.
21. Raboni S.M., Nogueira M.B., Tsuchiya L.R., et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003, 76:142-146.
22. Whimbey E., Englund J.A., Couch R.B. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997, 102:10-18.
23. Ghosh S., Champlin R.E., Englund J., et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000, 25:751-755.
24. Hall C.B., Douglas R.G. Modes of transmission of RSV. J Pediatr 1981, 99:100.
25. Hall C.B., Douglas R.G., Schnabel K.C., Geiman J.M. Infectivity of respiratory RSV by various routes of inoculation. Infect Immun 1982, 33:779.
26. Hall C.B., Douglas R.G., Geiman J.M. Quantitative shedding patterns of respiratory syncytial virus in infants. J Infect Dis 1975, 132:151.
27. Gala C.L., Hall C.B., Schnabel K.C., et al. The use of eye nose goggles to control nosocomial respiratory syncytial virus infection. JAMA 1986, 256:2706.
28. Tablan O.C., Anderson L.J., Besser R., et al. Guidelines for preventing health care-associated pneumonia, 2003: recommendations of CDC and healthcare infection control practice advisory committee. MMWR Recomm Rep 2004, 53:1.
29. Krasinski K., LaCouture R., Holzman R.S., et al. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission. J Pediatr 1990, 116:894.
30. Abadesso C., Almeida H.I., Virella D., Carreiro M.H., Machado M.C. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. J Hospital Infect 2004, 58:38-41.
31. Scott L.J., Lamb H.M. Palivizumab. Drugs 1999, 58:305-311.
32. The Impact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
33. Singelton R., Dooley L., Bruden D., et al. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003, 22(6):540-555.
34. Palivizumab Outcomes Study Group Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003, 35:484-489.
35. Cohen A.H., Sorrentino M., Powers T. Effectiveness of palivizumab for preventing serious RSV disease. J Respir Dis 2000, 2:S30-S32.
36. Lacaze-Masmonteil T., Rozé J.C., Fauroux B. French Pediatricians' Group of Synagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxis. Pediatr Pulmonol 2002, 34:181-188.
37. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003, 22:823-827.
38. Grimaldi M., Gouyon B., Sagot P., et al. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007, 42:189-192.
39. Cohen S.A., Zanni R., Cohen A., et al. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2008, 29:382-387.
40. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003, 12:1442-1446.
41. Thomas N.J., Hollenbeak C.S., Ceneviva G.D., et al. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J Pediatr Hematol Oncol 2007, 29:227-232.
42. Boeckh M., Berrey M.M., Bowden R.A., et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001, 184:350-354.
43. Georgescu G., Chemaly R.F. Palivizumab: where to from here?. Expert Opin Biol Ther 2009, 9:139-147.
44. Forbes M. Strategies for preventing respiratory syncytial virus. Am J Health Syst Pharm 2008, 65(Suppl 8).
45. Salcedo S., Vinzo J., Calico I., et al. Administration of palivizumab during a nosocomial outbreak in a neonatal unit Abstract P241, presented at the XVII European Congress of Perinatal Medicine, Porto Portugal. Prenatal Neonatal Med 2000, 5:180.
46. Cox R.A., Rao P., Brandon-Cox C. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect 2001, 48:186-192.
47. Kilani R.A. Respiratory syncytial virus (RSV) outbreak in the NICU: description of eight cases. J Trop Pediatr 2002, 48:118-122.
48. Heerens A.T., Marshall D.D., Bose C.L. Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit. J Perinatol 2002, 22:306-307.
49. Halasa N.B., Williams J.V., Wilson G.J., et al. Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 2005, 24:1040-1044.
50. Kurz H., Herbich K., Janata O., et al. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units. J Hosp Infect 2008, 70:246-252.
51. Jones B.L., Clark S., Curran E.T., et al. Control of an outbreak of respiratory syncytial virus infection in immunocompromised adults. J Hosp Infect 2000, 44:53-57.
52. Sorvillo F.J., Huie S.F., Strassburg M.A., et al. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J Infect 1984, 9:252-256.
53. Huang F.-L., Chen P.-Y., Shi Z.Y., et al. An unusual respiratory syncytial virus nosocomial outbreak in an adult psychiatry ward. Jpn J Infect Dis 2009, 62:61-62.
54. Caram L.B., Chen J., Taggart E.W., et al. Respiratory syncytial virus outbreak in a long-term care facility detected using reverse transcriptase polymerase chain reaction: an argument for real-time detection methods. J Am Geriatr Soc 2009, 57:482-485.